Adicet Bio (ACET) vs Hyperion DeFi (HYPD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Adicet Bio (ACET) has outperformed Hyperion DeFi (HYPD) over the past year, losing 54.7% versus a loss of 61.6%. Over five years, ACET leads with a -95.2% price change compared with -99.2% for HYPD. Adicet Bio is the larger company by market cap ($53.8 million vs $50.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACET | HYPD |
|---|---|---|
| Share price | $5.75 | $3.29 |
| Market cap | $53.84M | $50.08M |
| 1-day change | -6.93% | -8.24% |
| YTD return | -26.60% | +0.84% |
| 1-year return | -54.72% | -61.60% |
| 5-year return | -95.20% | -99.15% |
| EPS (TTM) | $-10.42 | $-6.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.44 | $9.50 |
| 52-week low | $5.75 | $2.34 |
| Distance from 52-week high | -67.02% | -65.32% |
| Average volume | 166.29K | 445.34K |
| Shares outstanding | 9.36M | 15.20M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
ACET vs HYPD FAQ
Which is bigger, Adicet Bio or Hyperion DeFi?
Adicet Bio (ACET) is larger, with a market capitalization of $53.84M compared with $50.08M for Hyperion DeFi (HYPD).
Which stock has performed better over the past year, ACET or HYPD?
ACET returned -54.72% over the past 12 months, compared with -61.60% for HYPD (price return, excluding dividends). Past performance does not predict future results.
Are Adicet Bio and Hyperion DeFi in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.